A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients

NCT01506947 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

65

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate to Severe Secondary Hyperparathyroidism
Stage 5 Chronic Kidney Diseases

Interventions

DRUG: Paricalcitol
DRUG: Darbepoetin alfa

Sponsor

AbbVie (prior sponsor, Abbott)